Data from the phase 3 METEOR trial presented at the 2016 annual meeting of the American Society of Clinical Oncology showed that cabozantinib reduced the risk of death in patients with advanced renal cell carcinoma by 34%, compared with everolimus.
Jason M. Broderick
Advertisement
Articles by Jason M. Broderick
A presscast held prior to the annual meeting of the American Society of Clincal Oncology presented interim results from the phase 3 ELOQUENT-2 trial. Adding elotuzumab to lenalidomide and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed-refractory multiple myeloma.
Advertisement
Latest Updated Articles
- Elotuzumab Combo Delays Myeloma Progression in Phase 3 Trial
Published: July 16th 2015 | Updated:
- Cabozantinib Improves Survival in Renal Cell Carcinoma
Published: July 22nd 2016 | Updated:
- Bevacizumab Aids Survival in Cervical Cancer
Published: August 23rd 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
4
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
5
